Candel Therapeutics, Inc. Common Stock (CADL) is a publicly traded Healthcare sector company. As of October 22, 2026, CADL trades at $8.53 with a market cap of $661.12M and a P/E ratio of -13.68. CADL moved +1.90% today. Year to date, CADL is +53.86%; over the trailing twelve months it is +52.46%. Its 52-week range spans $4.25 to $14.00. Analyst consensus is strong buy with an average price target of $20.80. Rallies surfaces CADL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival with aglatimagene plus valacyclovir after ICI failure: Candel Therapeutics reported final Phase 2a results in advanced NSCLC patients whose cancers did not respond adequately to checkpoint inhibitors, with median overall survival of 24.5 months. The company said the regimen is being evaluated against docetaxel in the global Phase 3 AURORA study.
| Metric | Value |
|---|---|
| Price | $8.53 |
| Market Cap | $661.12M |
| P/E Ratio | -13.68 |
| EPS | $-0.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.00 |
| 52-Week Low | $4.25 |
| Volume | 11.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-38.18M |
| Gross Margin | 0.00% |
5 analysts cover CADL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.80.